Eli Lilly and Company $LLY Shares Sold by Artisan Partners Limited Partnership

Artisan Partners Limited Partnership decreased its stake in shares of Eli Lilly and Company (NYSE:LLY) by 22.4% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 30,280 shares of the company’s stock after selling 8,759 shares during the quarter. Artisan Partners Limited Partnership’s holdings in Eli Lilly and Company were worth $23,604,000 at the end of the most recent reporting period.

A number of other institutional investors also recently bought and sold shares of LLY. Wealth Preservation Advisors LLC acquired a new position in shares of Eli Lilly and Company during the 1st quarter worth approximately $27,000. Financial Gravity Companies Inc. acquired a new stake in shares of Eli Lilly and Company in the second quarter worth approximately $31,000. Blume Capital Management Inc. raised its position in shares of Eli Lilly and Company by 46.7% in the second quarter. Blume Capital Management Inc. now owns 44 shares of the company’s stock valued at $34,000 after buying an additional 14 shares during the last quarter. IMG Wealth Management Inc. purchased a new position in Eli Lilly and Company in the 2nd quarter worth approximately $35,000. Finally, TD Capital Management LLC boosted its holdings in shares of Eli Lilly and Company by 129.2% during the 1st quarter. TD Capital Management LLC now owns 55 shares of the company’s stock worth $46,000 after purchasing an additional 31 shares during the last quarter. 82.53% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

LLY has been the topic of several recent research reports. Loop Capital set a $950.00 price target on shares of Eli Lilly and Company in a research report on Monday, November 10th. Leerink Partners raised Eli Lilly and Company from a “market perform” rating to an “outperform” rating and lifted their price objective for the company from $886.00 to $1,104.00 in a research note on Monday, November 10th. Sanford C. Bernstein reissued an “outperform” rating on shares of Eli Lilly and Company in a research report on Monday, November 3rd. BMO Capital Markets upped their target price on shares of Eli Lilly and Company from $930.00 to $1,100.00 and gave the stock an “outperform” rating in a research note on Thursday, November 6th. Finally, DZ Bank raised Eli Lilly and Company from a “hold” rating to a “strong-buy” rating in a research report on Thursday, August 14th. Three research analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating and seven have assigned a Hold rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $1,027.95.

Eli Lilly and Company Trading Up 1.4%

Shares of Eli Lilly and Company stock opened at $1,058.05 on Friday. The company has a 50-day moving average of $855.89 and a two-hundred day moving average of $787.66. The stock has a market cap of $1.00 trillion, a PE ratio of 69.15, a price-to-earnings-growth ratio of 1.21 and a beta of 0.43. Eli Lilly and Company has a 12-month low of $623.78 and a 12-month high of $1,066.65. The company has a current ratio of 1.28, a quick ratio of 1.00 and a debt-to-equity ratio of 1.86.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings data on Thursday, October 30th. The company reported $7.02 earnings per share for the quarter, topping analysts’ consensus estimates of $6.42 by $0.60. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. The business had revenue of $17.60 billion during the quarter, compared to analysts’ expectations of $16.09 billion. During the same period last year, the company posted $1.18 EPS. The company’s revenue was up 53.9% on a year-over-year basis. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. On average, research analysts anticipate that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Eli Lilly and Company Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Wednesday, December 10th. Shareholders of record on Friday, November 14th will be issued a $1.50 dividend. This represents a $6.00 dividend on an annualized basis and a dividend yield of 0.6%. The ex-dividend date is Friday, November 14th. Eli Lilly and Company’s dividend payout ratio (DPR) is 29.35%.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.